Compare BFH & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFH | WVE |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | N/A | 2015 |
| Metric | BFH | WVE |
|---|---|---|
| Price | $79.99 | $15.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 16 |
| Target Price | ★ $67.43 | $29.94 |
| AVG Volume (30 Days) | 719.9K | ★ 14.5M |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | ★ 9.68 | N/A |
| Revenue | ★ $2,509,000,000.00 | $109,230,000.00 |
| Revenue This Year | $58.71 | N/A |
| Revenue Next Year | $3.48 | $16.00 |
| P/E Ratio | $8.29 | ★ N/A |
| Revenue Growth | 1.70 | ★ 103.75 |
| 52 Week Low | $38.21 | $5.28 |
| 52 Week High | $80.41 | $21.73 |
| Indicator | BFH | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 72.38 | 53.45 |
| Support Level | $73.78 | $14.46 |
| Resistance Level | $78.98 | $19.50 |
| Average True Range (ATR) | 1.72 | 1.41 |
| MACD | -0.06 | -0.57 |
| Stochastic Oscillator | 93.31 | 19.64 |
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.